We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Buy Masimo (MASI) Stock Right Now
Read MoreHide Full Article
Masimo Corporation (MASI - Free Report) has been gaining investor confidence on continued positive results. Over the past year, the stock has rallied 57% compared with the industry’s 9.4% rise. Also, the company has outperformed the S&P 500’s 8.2% rise.
The company has an encouraging earnings surprise history, having outpaced the Zacks Consensus Estimate in each of the trailing three quarters, the average being 7.1%. Notably, the consecutive beats underline its operating efficiency. A solid view for 2019 and a slew of developments are working in favor of the stock.
With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive investment pick for now.
What’s Working in Favor?
Solid View
For 2019, Masimo expects total revenues of $912 million, reflecting year-over-year growth of 10.7% and 9.9% at constant currency. Adjusted product earnings per diluted share of $3.08 is expected to increase 16.2% from 2018.
Adjusted EBITDA is projected at 30.4% for 2019.
Developments
Masimo has seen a slew of positive developments of late.
Additionally, St. Luke’s, a regional network of hospitals, has expanded their use of a variety of Masimo technologies, which has led to impressive outcomes. Notably, St. Luke’s has been utilizing Masimo’s flagship products, like Masimo Patient SafetyNet, Masimo Root patient monitoring, Masimo Radius-7 tetherless and wearable Pulse CO-Oximeters.
Moreover, Masimo’s Next Generation SedLine brain function monitoring for pediatric patients received CE Mark. With this approval, the Next Generation SedLine are available for all patients a year old and above in countries which accept the CE Mark.
Product Launches
In recent times, Masimo has launched a number of products like RAS-45, an acoustic respiration sensor for rainbow Acoustic Monitoring (RAM), for treating infant and neonatal patients. Additionally, Masimo announced the launch of Doctella, a home-based patient engagement and remote care automation platform.
The Zacks Consensus Estimate for first-quarter earnings per share is pegged at 75 cents. The same for revenues stands at $223.2 million, indicating a 4.8% rise.
The Zacks Consensus Estimate for full-year earnings is at $3.08, showing 1.7% growth from 2018. The same for revenues stands at $912.9 billion, indicating a 6.4% rise.
Bottom Line
Masimo seems to be positioned for growth on a solid view for 2019 and a series of encouraging developments. The company's long-term earnings growth rate of 15.6% supports our view.
Varian Medical's long-term earnings are expected to grow 8%.
Penumbra has a long-term earnings growth rate of 20.9%.
Wright Medical’s long-term earnings growth is projected at 11.3%.
Will you retire a millionaire?
One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”
Image: Bigstock
Here's Why You Should Buy Masimo (MASI) Stock Right Now
Masimo Corporation (MASI - Free Report) has been gaining investor confidence on continued positive results. Over the past year, the stock has rallied 57% compared with the industry’s 9.4% rise. Also, the company has outperformed the S&P 500’s 8.2% rise.
The company has an encouraging earnings surprise history, having outpaced the Zacks Consensus Estimate in each of the trailing three quarters, the average being 7.1%. Notably, the consecutive beats underline its operating efficiency. A solid view for 2019 and a slew of developments are working in favor of the stock.
With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive investment pick for now.
What’s Working in Favor?
Solid View
For 2019, Masimo expects total revenues of $912 million, reflecting year-over-year growth of 10.7% and 9.9% at constant currency. Adjusted product earnings per diluted share of $3.08 is expected to increase 16.2% from 2018.
Adjusted EBITDA is projected at 30.4% for 2019.
Developments
Masimo has seen a slew of positive developments of late.
Last month, the company announced FDA clearance of the Rad-67 Pulse CO-Oximeter with Spot-check Next Generation SpHb. (Read More: Masimo Gets FDA Clearance for Rad-67 Monitoring Device)
Additionally, St. Luke’s, a regional network of hospitals, has expanded their use of a variety of Masimo technologies, which has led to impressive outcomes. Notably, St. Luke’s has been utilizing Masimo’s flagship products, like Masimo Patient SafetyNet, Masimo Root patient monitoring, Masimo Radius-7 tetherless and wearable Pulse CO-Oximeters.
Moreover, Masimo’s Next Generation SedLine brain function monitoring for pediatric patients received CE Mark. With this approval, the Next Generation SedLine are available for all patients a year old and above in countries which accept the CE Mark.
Product Launches
In recent times, Masimo has launched a number of products like RAS-45, an acoustic respiration sensor for rainbow Acoustic Monitoring (RAM), for treating infant and neonatal patients. Additionally, Masimo announced the launch of Doctella, a home-based patient engagement and remote care automation platform.
Masimo Corporation Price and Consensus
Masimo Corporation Price and Consensus | Masimo Corporation Quote
Which Way Are Estimates Treading?
The Zacks Consensus Estimate for first-quarter earnings per share is pegged at 75 cents. The same for revenues stands at $223.2 million, indicating a 4.8% rise.
The Zacks Consensus Estimate for full-year earnings is at $3.08, showing 1.7% growth from 2018. The same for revenues stands at $912.9 billion, indicating a 6.4% rise.
Bottom Line
Masimo seems to be positioned for growth on a solid view for 2019 and a series of encouraging developments. The company's long-term earnings growth rate of 15.6% supports our view.
Key Picks
Other top-ranked stocks in the broader medical space are Varian Medical , Penumbra (PEN - Free Report) , Wright Medical , each carrying a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Varian Medical's long-term earnings are expected to grow 8%.
Penumbra has a long-term earnings growth rate of 20.9%.
Wright Medical’s long-term earnings growth is projected at 11.3%.
Will you retire a millionaire?
One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”
Click to get it free >>